US Stock Insider Trading | Xeris Biopharma disclosed two insider trading transactions on March 5

K-LinePoet · 2026-04-09T10:21:48+00:00

On March 5, 2026, Xeris Biopharma executive Pieper Steven purchased 27.9k shares, along with a transaction of 14k shares; on the same day, Hecht Beth sold 16.6k shares and 100 shares. The company focuses on biopharmaceuticals, dedicated to improving patients' lives.

K-LinePoet

2026-04-09 10:21:48

Abstract generation in progress

On March 5, 2026, Xeris Biopharma (XERS) disclosed two insider trading transactions. Executive Pieper Steven purchased 27.9k shares.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 5, 2026	Executive	Pieper Steven	March 5, 2026	Buy	27.9k	4.09	114.1k
March 5, 2026	Executive	Pieper Steven	March 5, 2026	Buy	14k	5.93	83.2k
March 4, 2026	Executive	Hecht Beth	March 2, 2026	Sell	16.6k	6.24	103.4k
March 4, 2026	Executive	Hecht Beth	March 2, 2026	Sell	100	7.06	706.00
February 25, 2026	Executive	Nguyen Anh Tu	February 24, 2026	Sell	29.3k	6.88	201.6k
February 2, 2026	Executive	McCulloch Kevin	January 31, 2026	Sell	126.1k	7.36	927.8k
February 2, 2026	Executive	Pieper Steven	January 31, 2026	Sell	205.5k	7.36	1.51M
February 2, 2026	Director	Shannon John Patrick Jr	January 31, 2026	Sell	345,000	7.36	2.51M
February 2, 2026	Executive	Hecht Beth	January 31, 2026	Sell	169.6k	7.36	1.25M
February 2, 2026	Executive	Hecht Beth	February 2, 2026	Sell	16.7k	7.45	124.1k

【Company Information】

Xeris Biopharma Holdings, Inc. was incorporated in 2005 under Delaware law. The company is dedicated to building an innovative, self-sustaining, growth-oriented biopharmaceutical company committed to improving patients’ lives by developing a series of clinically meaningful therapies and commercializing them. The company has a unique advantage through three commercial products and proprietary formulation science (XeriSol and XeriJect) to achieve this goal, thereby establishing partnerships and strengthening candidate products.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.